- Home
- APXT vs AUTL Comparison
APXT vs AUTL Comparison
Compare APXT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.00
HOLD
Current Price
$1.59
Company Overview
Basic Information| Metric | APXT | AUTL |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United Kingdom |
| Employees | 4 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.3M | 431.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | APXT | AUTL |
|---|---|---|
| Price | $10.00 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 28.9K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $84.74 |
| Revenue Next Year | N/A | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $9.87 | $1.15 |
| 52 Week High | $10.00 | $2.70 |
Technical Indicators
Market Signals| Indicator | APXT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 59.85 |
| Support Level | N/A | $1.22 |
| Resistance Level | $10.00 | $1.69 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 92.86 | 74.03 |
Price Performance
Historical Comparison APXT
AUTL
About APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.